The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized ...

I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if ...

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for ...

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three ...

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...